Double Bottom with Handle? EQ has formed a double bottom on the daily chart and now working on the handle with possible accumulation.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.1311 USD
−13.34 M USD
36.08 M USD
17.43 M
About Equillium, Inc.
Sector
Industry
CEO
Bruce D. Steel
Website
Headquarters
La Jolla
Founded
2017
FIGI
BBG00LSL8C10
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March, 2017 and is headquartered in La Jolla, CA.
EQ yearly cup with handleThe stock seems to be forming the handle of a huge cup (and double bottom) from Aug. 2022 high to Feb 2023 high.
Monster move is comingPrice has started to diverge from the moving averages on higher TFs. Nice volume accumulation. Notice how drop to 4 got bought up quickly.
It tested supply zone at 6 and continues to push higher. Now news likely to hit any day to spike it to 10 or even 13.
EQ Watch for Resistance Breakout. Bullish FridayEQ reached top mover status as a gainer one day and a loser the following day.
Thursday, EQ was up +1.49% pre-market.
I predict stock moves at a steady pace toward $24 price target.
EQ is a mall biotech company researching Alzheimer's medicine.
Healthcare is our third-largest sector ($6.2 T).
EQ Bullish Target $24EQ soared after news on Alziemers drug.
Following the spike in volume (OBV), there is a pullback.
Now, I predict a bullish rise to the $24 target.
Please always do your own research.
This is not advice.
I'm here to learn.
Thoughts?
EQ, a top quarterly gainer, rising +795%.Expect Uptrend reversalEquillium (EQ, $26.5) was one of top quarterly gainers, jumping +795.27% to $26.5 per share. Tickeron A.I.dvisor analyzed 383 stocks in the Biotechnology Industry over the last three months, and discovered that 298 of them (77.69%) charted an Uptrend while 85 of them (22.31%) trended down. Tickeron
Itolizumab Reduces Mortality in Patients Hospitalized with COVIDClinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19
Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon
Biocon has received emergency use approval from Drugs Controller General of India for
it is bought with the rumor and it is sold with the news #EQequillium EQ-explodes-730%-positive-covid
it is bought with the rumor and it is sold with the news
“We note the trial in hospitalized COVID-19 patients was small (n=30), open-label and on top of standard of care, and little data were shared but according the Biocon/EQ press releases, the itolizumab
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of EQ is 0.7110 USD — it has decreased by −1.25% in the past 24 hours. Watch Equillium, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Equillium, Inc. stocks are traded under the ticker EQ.
EQ stock has risen by 7.13% compared to the previous week, the month change is a −34.17% fall, over the last year Equillium, Inc. has showed a 42.20% increase.
We've gathered analysts' opinions on Equillium, Inc. future price: according to them, EQ price has a max estimate of 8.00 USD and a min estimate of 2.00 USD. Watch EQ chart and read a more detailed Equillium, Inc. stock forecast: see what analysts think of Equillium, Inc. and suggest that you do with its stocks.
EQ stock is 5.69% volatile and has beta coefficient of 1.42. Track Equillium, Inc. stock price on the chart and check out the list of the most volatile stocks — is Equillium, Inc. there?
Today Equillium, Inc. has the market capitalization of 25.19 M, it has increased by 1.47% over the last week.
Yes, you can track Equillium, Inc. financials in yearly and quarterly reports right on TradingView.
Equillium, Inc. is going to release the next earnings report on Mar 26, 2025. Keep track of upcoming events with our Earnings Calendar.
Equillium, Inc. revenue for the last quarter amounts to 12.16 M USD, despite the estimated figure of 11.55 M USD. In the next quarter, revenue is expected to reach 0.00 USD.
EQ net income for the last quarter is −7.00 K USD, while the quarter before that showed 468.00 K USD of net income which accounts for −101.50% change. Track more Equillium, Inc. financial stats to get the full picture.
No, EQ doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 25, 2024, the company has 44.00 employees. See our rating of the largest employees — is Equillium, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Equillium, Inc. EBITDA is −6.63 M USD, and current EBITDA margin is −39.90%. See more stats in Equillium, Inc. financial statements.
Like other stocks, EQ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Equillium, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Equillium, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Equillium, Inc. stock shows the sell signal. See more of Equillium, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.